With the broader stock market selling off, it’s amazing to see a company’s share price defy the near-term trend and appreciate in value.
Time
and time again, Johnson & Johnson (JNJ) gets bid when the broader
market faces convulsion. It’s a powerful signal, and there is still a
great deal of angst among institutional investors; they still want those
dividends and the relative safety of earnings that are predictable.
Johnson
& Johnson has been—and continues to be—an excellent wealth creator.
The stock’s been bouncing off $95.00 a share the last while and just
recently, it seems to have broken past this price ceiling.
There’s
not a lot new with this position. One Wall Street firm recently boosted
its earnings expectations for the company in 2015. Sales growth is
expected to be in the low single-digits this year, but annual earnings
growth combined with dividends should be in the low double digits once
again. The company reports its first-quarter numbers on April 15.
There’s
definitely been a change in investor sentiment regarding speculative
positions. Biotechnology stocks, which have been the market’s multiyear
winning sector have finally seen investors book profits. It’s been long
overdue and from a market perspective, is a healthy development for the
primary trend.
The
selling migrated to large-cap technology names and the shakedown just
might last a while longer. Anything can happen during an earnings
season, but a “sell in May and go away” type of scenario is a real
possibility again this year.
Other
blue chip names that are also defying the market’s recent action
include 3M Company (MMM), Union Pacific Corporation (UNP),
Kimberly-Clark Corporation (KMB), Microsoft Corporation (MSFT),
Caterpillar Inc. (CAT), United Technologies Corporation (UTX), and The
Walt Disney Company (DIS).
Even
though the Dow Jones Industrial Average pulled back with the NASDAQ
Composite, many component companies are either pushing or trading right
near their highs. This price resilience among the big names is important
and makes me worry less about a change in the market’s primary trend.
Johnson
& Johnson boasts a forward price-to-earnings ratio of 15, according
to Morningstar. The company’s been increasing its earnings per share
consistently the last few years, along with its annual dividends.
In 2009, the company paid out $1.93 per share. This grew to $2.25 by 2011 and to $2.59 in 2013.
Even
though this stock has gone up tremendously the last few years, it can
keep doing so if it meets or beats consensus, because institutional
investors want the company’s earnings reliability. Portfolio safety and
risk are two very important attributes and recent market action
illustrates how essential it is not to let investment risk and portfolio
management go by the wayside.
Johnson
& Johnson has proven itself to be a dividend-paying stock that’s
worth considering when it’s down. According to history, it’s not
typically a company that’s down in price for long. Stocks
that outperform the broader market over the long haul make for great
bedrock positions in an equity portfolio. Johnson & Johnson’s been
doing this for years.
To get more information or Regular updates of stock market just join us.
You can make your stock market trading more profitable by using Robotic Trading System.
This is the fully robotic trading system which allows you to create
your your own trading strategies. No need to follow others make your own
way to get maximum profit. If you want to check the demo of this system
just fill the form given below.
To get demo of Robotic Trading system just fill these below details
To get demo of Robotic Trading system just fill these below details
0 comments:
Post a Comment